Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 33,180 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
Interventions: Ifetroban, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 7 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 7 more

Conditions: Obesity
Interventions: CP-945,598 Treatment A, CP-945,598 Treatment B, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2,536 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 74
States / cities: Fairhope, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more

Conditions: Healthy
Interventions: BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Opioid Induced Constipation (OIC)
Interventions: placebo, NKTR-118; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 33
States / cities: Huntsville, Alabama • Pinson, Alabama • Tucson, Arizona + 30 more

Conditions: HIV Infections, AIDS-Associated Nephropathy
Interventions: Prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 4 more

Conditions: Agitation, Alzheimer's Type Dementia
Interventions: Masupirdine 50 mg, Masupirdine 100 mg, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 27
States / cities: Anaheim, California • Costa Mesa, California • Encino, California + 17 more

Conditions: Inflammation and Pain Following Ocular Surgery
Interventions: Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 6
States / cities: Garden Grove, California • Fort Myers, Florida • Kansas City, Missouri + 3 more

Conditions: Stress Disorders, Post-Traumatic
Interventions: Pregnenolone or Placebo; Drug
Lead sponsor: Durham VA Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Schizophrenia
Interventions: LY2140023, Placebo; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Oakland, California • San Diego, California • Torrance, California + 5 more

Conditions: Functional Dyspepsia
Interventions: Glutamine, Placebo; Drug
Lead sponsor: David J. Cangemi; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Alzheimer Dementia
Interventions: Human Mesenchymal Stem Cells and Lactated Riunger's Solution, Placebo; Drug · Other
Lead sponsor: Stemedica Cell Technologies, Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Nicotine Dependence
Interventions: nicotine patch, nicotine lozenge, nicotine patch + nicotine lozenge, bupropion, bupropion + lozenge, placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Epistaxis, Blood Pressure
Interventions: Oxymetazoline 0.05%, Phenylephrine 0.25%, Lidocaine 1% plus epinephrine 1:100,000, Bacteriostatic 0.9% NaCL; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: COVID-19
Interventions: VYD2311-SD, VYD2311-MD, Placebo; Drug
Lead sponsor: Invivyd, Inc.; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 1,770 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 20
States / cities: Long Beach, California • San Diego, California • Orlando, Florida + 17 more

Conditions: Migraine
Interventions: XC101-D13H, Placebo; Drug
Lead sponsor: Xoc Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 80
States / cities: Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more

Conditions: Dyslipidemia
Interventions: PPAR alpha, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 54
States / cities: Hoover, Alabama • Fayetteville, Arkansas • San Diego, California + 51 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Divalproex Sodium Extended-Release Tablets, placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Anxiety, Depression, Insomnia, Sleep Quality
Interventions: Alpha-Stim AID CES (Active Comparator), Alpha-Stim AID CES (Sham Comparator); Device
Lead sponsor: Christina Murphey, RN, PhD; Individual
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Austin, Texas • Corpus Christi, Texas

Conditions: Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions: Lofexidine, Placebo oral tablet; Drug
Lead sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance; Other
Eligibility: 18 Years to 70 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
Interventions: Panzyga, Placebo; Biological · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 15
States / cities: St. Petersburg, Florida • Columbus, Georgia • Macon, Georgia + 10 more

Conditions: Diabetic Neuropathy
Interventions: DA-9801 300mg, DA-9801 600mg, DA-9801 900mg, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 14
States / cities: Lakewood, California • Walnut Creek, California • Milford, Connecticut + 10 more

Conditions: Pyoderma Gangrenosum
Interventions: gevokizumab, Placebo, gevokizumab open-label; Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Coral Gables, Florida • North Miami Beach, Florida • Ann Arbor, Michigan + 9 more

Conditions: Healthy Volunteers
Interventions: BMS-986325, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Cypress, California

Search by objective public record fields.

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs

A Physical Dependence Study in Schizophrenia

A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia

Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease

Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms

The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.

Study of VYD2311 for the Prevention of COVID-19

Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

A Study in People With Abnormal Fat Levels in the Blood

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

New Mothers Alpha-Stim

Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Study of DA-9801 to Treat Diabetic Neuropathy

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants